Center of Hematology and Bone Marrow Transplantation Fundeni Clinical Institute Bucharest Romania

Centre for Clinical Transfusion Research Sanquin Research Leiden The Netherlands

Department of Clinical Epidemiology Leiden University Medical Center Leiden The Netherlands

Department of Clinical Hematology Institute of Hematology and Blood Transfusion Praha Czech Republic

Department of Endocrinology University of Groningen University Medical Center Groningen Groningen The Netherlands

Department of Haematology 1st Department of Propedeutic Internal Medicine National and Kapodistrian University of Athens Medical School Laikon General Hospital Athens Greece

Department of Haematology Warrington and Halton Teaching Hospitals NHS foundation Trust Cheshire UK

Department of Hematology Aberdeen Royal Infirmary Aberdeen UK

Department of Hematology Airedale NHS Trust Airdale UK

Department of Hematology Blackpool Victoria Hospital Blackpool Lancashire UK

Department of Hematology Coltea Clinical Hospital Bucharest Romania

Department of Hematology Radboud University Medical Center Nijmegen The Netherlands

Department of Hematology Royal Bournemouth Hospital Bournemouth UK

Department of Laboratory Medicine Hepcidinanalysis com and Radboudumc Expertise Center for Iron Disorders Radboud University Medical Center Nijmegen The Netherlands

Department of Medicine Division of Hematology Karolinska Institutet Stockholm Sweden

Department of Medicine Division of Hematology University of Patras Medical School Patras Greece

Department of Medicine Sect of Hematology and Coagulation Sahlgrenska University Hospital Göteborg Sweden

Epidemiology and Cancer Statistics Group University of York York UK

Nijmegen Center for Molecular Life Sciences Department of Tumor Immunology Radboud University Medical Center Nijmegen The Netherlands

St James's Institute of Oncology Leeds Teaching Hospitals Leeds UK

Zobrazit více v PubMed

Cazzola M, Della Porta MG, Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2008;1:166–75. doi: 10.1182/asheducation-2008.1.166. PubMed DOI

Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23:7594–603. doi: 10.1200/JCO.2005.01.7038. PubMed DOI

Leitch HA, Fibach E, Rachmilewitz E. Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies. Crit Rev Oncol Hematol. 2017;113:156–70. doi: 10.1016/j.critrevonc.2017.03.002. PubMed DOI

Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124:873–81. doi: 10.1182/blood-2014-03-563221. PubMed DOI PMC

de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, et al. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. Haematologica. 2018;103:69–79. doi: 10.3324/haematol.2017.171884. PubMed DOI PMC

Porter JB, de Witte T, Cappellini MD, Gattermann N. New insights into transfusion-related iron toxicity: Implications for the oncologist. Crit Rev Oncol Hematol. 2016;99:261–71. doi: 10.1016/j.critrevonc.2015.11.017. PubMed DOI

Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012;1823:1434–43. doi: 10.1016/j.bbamcr.2012.01.014. PubMed DOI PMC

Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46:678–84. doi: 10.1038/ng.2996. PubMed DOI PMC

Ye ZW, Zhang J, Townsend DM, Tew KD. Oxidative stress, redox regulation and diseases of cellular differentiation. Biochim Biophys Acta. 2015;1850:1607–21. doi: 10.1016/j.bbagen.2014.11.010. PubMed DOI PMC

Pimková K, Chrastinová L, Suttnar J, Štikarová J, Kotlín R, Čermák J, et al. Plasma levels of aminothiols, nitrite, nitrate, and malondialdehyde in myelodysplastic syndromes in the context of clinical outcomes and as a consequence of iron overload. Oxid Med Cell Longev. 2014;2014:416028. doi: 10.1155/2014/416028. PubMed DOI PMC

Pilo F, Angelucci E. A storm in the niche: Iron, oxidative stress and haemopoiesis. Blood Rev. 2018;32:29–35. doi: 10.1016/j.blre.2017.08.005. PubMed DOI

de Souza GF, Barbosa MC, Santos TE, Carvalho TM, de Freitas RM, Martins MR, et al. Increased parameters of oxidative stress and its relation to transfusion iron overload in patients with myelodysplastic syndromes. J Clin Pathol. 2013;66:996–8. doi: 10.1136/jclinpath-2012-201288. PubMed DOI

Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, et al. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS ONE. 2011;6:e23109. doi: 10.1371/journal.pone.0023109. PubMed DOI PMC

Ambaglio I, Malcovati L, Papaemmanuil E, Laarakkers CM, Della Porta MG, Gallì A, et al. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica. 2013;98:420–3. doi: 10.3324/haematol.2012.077446. PubMed DOI PMC

Zipperer E, Post JG, Herkert M, Kündgen A, Fox F, Haas R, et al. Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome. Ann Hematol. 2013;92:1617–23. doi: 10.1007/s00277-013-1839-5. PubMed DOI

Somatic mutations and DNA methylation identify a subgroup of poor prognosis within lower-risk myelodysplastic syndromes